This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Neuralstem President And CEO To Present 2014 Trials Overview At 2014 Biotech Showcase

ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the sixth annual Biotech Showcase ( http://www.ebdgroup.com/bts/index.php) in San Francisco on Tuesday, January 14, 3:30 p.m. PT, in Room Powell (Track D). Garr will present a business overview, including updates on ongoing and planned clinical trials. Garr will provide a progress update on NSI-566 cell therapy trials including ALS Phase II, chronic spinal cord injury Phase I, and ischemic stroke Phase I/II in China. Garr will also update the status of its neurogenic NSI-189 small molecule drug which stimulates new neuron growth in the hippocampus, which completed a Phase I safety trial, in major depressive disorder, in the fourth quarter of 2013.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

The audio webcast will be available in real-time at http://www.media-server.com/m/p/p65iz6pt, with replay beginning approximately two hours following the presentation, and archived for one year. The webcast link will also be posted on the Investor Center home page on Neuralstem's website: www.neuralstem.com.

About Neuralstem

Neuralstem's patented technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem's NSI-566 spinal cord-derived stem cell therapy is in Phase II clinical trials for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the Company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury and ischemic stroke. The Company has received FDA approval to commence a Phase I safety trial in chronic spinal cord injury.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,047.81 -22.59 -0.12%
S&P 500 2,113.16 -1.33 -0.06%
NASDAQ 5,003.0120 -13.9170 -0.28%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs